Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D expenses that double every quarter, complex collaboration revenue notes, and pages of clinical trial risk factors—Cue Biopharma’s SEC filings can feel like a scientific paper wrapped in legal jargon. Yet those disclosures hide the signals investors crave: when Immuno-STAT trials hit a milestone, how much cash runway remains, and whether insiders are quietly buying shares.
StockTitan’s AI decodes each document in minutes. Need the Cue Biopharma quarterly earnings report 10-Q filing? You’ll get real-time alerts plus an AI-powered summary that translates biotech accounting into plain English. Wondering about Cue Biopharma insider trading Form 4 transactions? We flag executive stock moves the moment they post to EDGAR and map them against upcoming data readouts. From the exhaustive annual report—your Cue Biopharma annual report 10-K simplified—to every 8-K material event explained, our platform covers every filing type with expert context and historical comparisons.
Here’s how professionals use the page:
- Track Cue Biopharma Form 4 insider transactions real-time to gauge management confidence before Phase 1/2 updates.
- Compare R&D spend across quarters without wading through footnotes�Cue Biopharma earnings report filing analysis makes it clear.
- Quickly locate equity-compensation tables inside the Cue Biopharma proxy statement executive compensation.
Whether you’re parsing an 8-K for FDA feedback or understanding Cue Biopharma SEC documents with AI, StockTitan turns dense biotech disclosures into actionable insight—no PhD required.
Cue Biopharma filed a Form S-8 to register securities under its 2025 Stock Incentive Plan, enabling the company to grant equity awards to employees, directors and other service providers. The registration statement incorporates by reference the company’s annual report for the fiscal year ended December 31, 2024, its quarterly reports for the quarters ended March 31, 2025 and June 30, 2025, and a set of current reports and other SEC filings, and it updates the company’s description of its common stock via Exhibit 4.2 to the 2024 annual report.
The filing omits plan narrative from Part I because those documents were provided separately to plan participants under Rule 428; exhibits included or incorporated by reference cover the 2025 Stock Incentive Plan, the amended and restated certificate of incorporation and bylaws, legal opinion and auditor consents, a power of attorney and the calculation of filing fee tables. The statement also summarizes the company’s indemnification framework for directors and officers, including indemnification agreements and directors� and officers� liability insurance.
Cue Biopharma reported continued clinical-stage operating losses while taking steps to bolster liquidity through financing and partnerships. The company held $27.5 million of cash and cash equivalents as of June 30, 2025 and reported a net loss of $20.7 million for the six months ended June 30, 2025 (net loss of $8.48 million for the quarter). Accumulated deficit was $362.6 million and weighted average shares outstanding increased to 84.86 million for the six-month period.
The company raised capital through a 2025 public offering that generated $18.0 million net proceeds, modest ATM proceeds during the period, and received a $10.1 million upfront payment from a collaboration and license agreement with Boehringer Ingelheim (BI) that also includes up to approximately $345 million in potential milestones and royalties. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes all Term Loans are due December 1, 2025.
Cue Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 to this Current Report and the company states that the information is being "furnished" rather than "filed," so it is not subject to the liability provisions of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference. The registrant’s common stock trades on the Nasdaq Capital Market under the symbol CUE.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
